Clinical Research Directory
Browse clinical research sites, groups, and studies.
Population Pharmacokinetics of Apixaban in Asian Patients With Atrial Fibrillation
Sponsor: Chulalongkorn University
Summary
The goal of this observational study is to learn about the variability of apixaban blood levels and identify the clinical factors that influence them in Asian patients with atrial fibrillation. The main questions it aims to answer are: 1. What are the specific pharmacokinetic parameters and their variabilities for apixaban in this patient population? 2. Which clinical factors, such as kidney function or body weight, are the primary predictors of how apixaban is cleared and distributed in the body? Participants will be asked to give consent to allow researchers to use their existing electronic outpatient medical records and previously collected blood concentration data for analysis.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
200
Start Date
2026-09-01
Completion Date
2027-04-30
Last Updated
2026-08-05
Healthy Volunteers
No
Conditions
Interventions
Apixaban
Apixaban is administered as an oral tablet in fixed doses of 2.5 mg or 5 mg twice daily. The intervention is provided as part of standard clinical care for patients diagnosed with non-valvular atrial fibrillation. For the purposes of this pharmacokinetic analysis, the intervention requires a minimum duration of 3 consecutive days of consistent dosing to ensure that the drug has reached steady-state plasma concentrations prior to data collection.
Locations (1)
Faculty of Medicine, Chulalongkorn University
Pathum Wan, Bangkok, Thailand